Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis
2019 ◽
Vol 58
(8)
◽
pp. 1059-1068
◽
2018 ◽
Vol 79
(3)
◽
pp. AB224
◽
2009 ◽
Vol 49
(2)
◽
pp. 162-175
◽
2018 ◽
Vol 44
(3)
◽
pp. 371-378
2015 ◽
Vol 55
(2)
◽
pp. 209-223
◽
2009 ◽
Vol 5
(4S_Part_8)
◽
pp. P253-P253
◽
2020 ◽
Vol 83
(6)
◽
pp. AB31
2018 ◽
Vol 58
(5)
◽
pp. 613-627
◽
2017 ◽
Vol 57
(3)
◽
pp. 355-365
◽
2016 ◽
Vol 33
(7)
◽
pp. 1657-1670
◽